Literature DB >> 19652610

Peripheral magnetic resonance angiography with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/kg) of gadobutrol at 3.0 T.

Matthias Voth1, Stefan Haneder, Kurt Huck, Alexandra Gutfleisch, Stefan O Schönberg, Henrik J Michaely.   

Abstract

PURPOSE: To prove the concept of peripheral continuous table movement (CTM) MR-angiography (MRA) in combination with high spatial and temporal resolution time-resolved TWIST-MRA in a single MR-examination at 3.0 T with a single dose (0.1 mmol/kg) of gadobutrol in total.
MATERIALS AND METHODS: We included 22 consecutive patients (15 m/7 f, mean age: 64 years) referred for peripheral MRA with clinical symptoms of peripheral arterial occlusive disease Fontaine stages II-IV. All of them underwent both CTM-MRA (TR: 2.4 ms/TE: 1.0 ms/flip angle: 21 degree) of the entire run-off vessels and TWIST-MRA (TR: 2.8 ms/TE: 1.1 ms/flip angle: 20 degree) of the calf station during a single MR-examination. All examinations were performed on a 3.0 T MR system (Tim Trio). Spatial resolution of the CTM-MRA datasets was technically limited to an acquired resolution of 1.2 x 1.2 x 1.96 mm3 reconstructed to 1.2 mm isotropic. The TWIST-MRA was acquired with 1.1 x 1.1 x 1.35 mm3 and reconstructed to 1.1 mm isotropic with a temporal resolution of 5.5 seconds in the calf station. A total of 0.1 mmol/kg BW gadobutrol diluted 1:1 with saline was injected at a flow rate of 1.5 mL/s of which 0.07 mmol/kg was administered for the CTM-MRA and 0.03 mmol/kg for the TWIST-MRA. CTM-MRA run off datasets were qualitatively assessed using a 4 point scale (4 = excellent, 1 = nondiagnostic) followed by TWIST-MRA datasets for the calf using the same scale. Additional relevant findings only visible in the TWIST-MRA were documented.
RESULTS: All datasets could be evaluated with a total of 397 assessable segments. CTM-MRA was diagnostic in 99% (393/397 segments) with image quality judged as excellent in 54% (213/397 segments), good in 42% (14/397), and moderate in 4% (14/397) of analyzed segments respectively. Nondiagnostic image quality was seen in 1% (4/397 segments). Venous overlay in the calf station was found in 27% (6/22 patients). TWIST-MRA was diagnostic in 100% (115/115 segments), throughout with good or excellent image quality. In 14 of 22 patients additional relevant findings were detected by TWIST-MRA.
CONCLUSION: Single-dose gadobutrol CTM-MRA in combination with a high spatial and temporal resolution TWIST-MRA at 3.0 T is a reliable technique with good image quality. Despite the use of single dose contrast agent large field of view coverage and dynamic images can be acquired. Because of its robustness, this imaging approach of the vasculature has great potential for a broad clinical use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652610     DOI: 10.1097/RLI.0b013e3181b4c26c

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  18 in total

1.  Magnetic resonance angiography (MRA) of the calf station at 3.0 T: intraindividual comparison of non-enhanced ECG-gated flow-dependent MRA, continuous table movement MRA and time-resolved MRA.

Authors:  Stefan Haneder; Ulrike I Attenberger; Philipp Riffel; Thomas Henzler; Stefan O Schoenberg; Henrik J Michaely
Journal:  Eur Radiol       Date:  2011-01-28       Impact factor: 5.315

2.  Magnetic resonance angiography of the carotid arteries: comparison of unenhanced and contrast enhanced techniques.

Authors:  Harald Kramer; Val M Runge; John N Morelli; Kenneth D Williams; L Gill Naul; Konstantin Nikolaou; Maximilian F Reiser; Bernd J Wintersperger
Journal:  Eur Radiol       Date:  2011-04-09       Impact factor: 5.315

3.  Prospective comparison of cartesian acquisition with projection-like reconstruction magnetic resonance angiography with computed tomography angiography for evaluation of below-the-knee runoff.

Authors:  Phillip M Young; Petrice M Mostardi; James F Glockner; Terri R Vrtiska; Thanila Macedo; Clifton R Haider; Stephen J Riederer
Journal:  J Vasc Interv Radiol       Date:  2013-03       Impact factor: 3.464

4.  Recent advances in 3D time-resolved contrast-enhanced MR angiography.

Authors:  Stephen J Riederer; Clifton R Haider; Eric A Borisch; Paul T Weavers; Phillip M Young
Journal:  J Magn Reson Imaging       Date:  2015-06-01       Impact factor: 4.813

5.  Three-station three-dimensional bolus-chase MR angiography with real-time fluoroscopic tracking.

Authors:  Casey P Johnson; Paul T Weavers; Eric A Borisch; Roger C Grimm; Thomas C Hulshizer; Christine C LaPlante; Phillip J Rossman; James F Glockner; Phillip M Young; Stephen J Riederer
Journal:  Radiology       Date:  2014-03-14       Impact factor: 11.105

6.  Time-resolved bolus-chase MR angiography with real-time triggering of table motion.

Authors:  Casey P Johnson; Clifton R Haider; Eric A Borisch; James F Glockner; Stephen J Riederer
Journal:  Magn Reson Med       Date:  2010-09       Impact factor: 4.668

7.  The impact of injector-based contrast agent administration in time-resolved MRA.

Authors:  Johannes Budjan; Ulrike I Attenberger; Stefan O Schoenberg; Hubertus Pietsch; Gregor Jost
Journal:  Eur Radiol       Date:  2017-12-07       Impact factor: 5.315

8.  Assessment of the kidneys: magnetic resonance angiography, perfusion and diffusion.

Authors:  Ulrike I Attenberger; John N Morelli; Stefan O Schoenberg; Henrik J Michaely
Journal:  J Cardiovasc Magn Reson       Date:  2011-11-15       Impact factor: 5.364

9.  Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla.

Authors:  M Voth; Henrik J Michaely; C Schwenke; B Vos; H Pietsch
Journal:  Eur Radiol       Date:  2010-09-01       Impact factor: 5.315

Review 10.  Innovations in the Endovascular Management of Critical Limb Ischemia: Retrograde Tibiopedal Access and Advanced Percutaneous Techniques.

Authors:  Jihad A Mustapha; Larry J Diaz-Sandoval; Fadi Saab
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.